<DOC>
	<DOC>NCT01366287</DOC>
	<brief_summary>The primary purpose of this study is to estimate the relative bioavailability and food effect of a PF-03882845 tablet as compared to a suspension formulation used in previous clinical studies.</brief_summary>
	<brief_title>A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years,Females must be of nonchildbearing potential. Body mass index of 17.5 to 30.5 kg/m2. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures. Serum potassium &gt;5 mEq/L at screening. Impaired kidney function (estimated GFR &lt;60 mL/min/1.73 m2). History of sensitivity to eplerenone, spironolactone, or related compounds.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Relative bioavailability</keyword>
	<keyword>food effect</keyword>
	<keyword>tablet</keyword>
	<keyword>suspension</keyword>
	<keyword>single dose</keyword>
	<keyword>crossover</keyword>
	<keyword>healthy subjects</keyword>
</DOC>